Gender differences in MRI studies on multiple sclerosis

Journal of the Neurological Sciences

Volumn 286, Issue 1-2, 2009, Pages 28-30

  Fazekas, Franz ^a   Enzinger, Christian ^a   Wallner Blazek, Mirja ^a   Ropele, Stefan ^a   Pluta Fuerst, Aga ^a   Fuchs, Siegrid ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Brain atrophy; Contrast enhancing lesions; Gender; MRI; Multiple sclerosis

Indexed keywords

ESTRADIOL; GADOLINIUM; SEX HORMONE; TESTOSTERONE;

ARTICLE; BRAIN ATROPHY; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; ESTRADIOL BLOOD LEVEL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HISTOPATHOLOGY; HORMONE DETERMINATION; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PRIORITY JOURNAL; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL;

FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; SEX FACTORS;

EID: 70349981427     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.07.025     Document Type: Article

References (22)

1. Orton S., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadormick A.D., and Ebers G.C. Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 5 11 (Nov 2006) 932-936
2. Tomassini V., and Pozzilli C. Sex hormones, brain damage and clinical course of Multiple Sclerosis. J Neurol Sci. 286 1-2 (2009) 35-39 (this issue)
3. Vukusic S. Confavreux C. Natural history of multiple sclerosis: risk factors and prognostic indicators. Curr Opin Neurol 20 3 (Jun 2007) 269-274
4. Debouverie M., Pittion-Vouyovitch S., Louis S., Guillemin F., and Lorsep Group. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 15 9 (Sep 2008) 916-921
5. Weinshenker B. Natural history of multiple sclerosis. Ann Neurol 1994 36 Suppl (1994) S6-S11
6. Filippi M., Rocca M., Arnold D., Bakshi R., Barkhof F., De Stefano N., et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. Eur J Neurol 13 4 (Apr 2006) 313-325
7. Ropele S., and Fazekas F. Magnetization transfer MR imaging in multiple sclerosis. Neuroimaging Clin N Am 19 1 (Feb 2009) 27-36
8. Rovaris M., Agosta F., Pagani E., and Filippi M. Diffusion tensor MR imaging. Neuroimaging. Clin N Am 19 1 (Feb 2009) 37-43
9. Weatherby S., Mann C., Davies M., Fryer A., Haq N., Strange R., et al. A pilot study of the relationship between gadolinium-enhancing lesions, gender effect and polymorphisms of antioxidant enzymes in multiple sclerosis. J Neurol 247 6 (Jun 2000) 467-470
10. Bansil S., Lee H., Jindal S., Holtz C., and Cook S. Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta Neurol Scand 99 2 (Feb 1999) 91-94
11. Kim S., Liva S., Dalal M., Verity M., and Voskuhl R. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology 52 6 (Apr 1999) 1230-1238
12. Pozzilli C., Tomassini V., Marinelli F., Paolillo A., Gasperini C., and Bastianello S. 'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol 10 1 (Jan 2003) 95-97
13. Tomassini V., Onesti E., Mainero C., Giugni E., Paolillo A., Salvetti M., et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 76 2 (Feb 2005) 272-275
14. Barkhof F., Held U., Simon J., Daumer M., Fazekas F., Filippi M., et al. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 65 9 (Nov 2005) 1447-1454
15. Li D., Held U., Petkau J., Daumer M., Barkhof F., Fazekas F., et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 66 9 (May 2006) 1384-1389
16. van Walderveen M., Lycklama A Nijeholt G., Adèr H., Jongen P., Polman C., Castelijns J., et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 58 1 (Jan 2001) 76-81
17. Tedeschi G., Lavorgna L., Russo P., Prinster A., Dinacci D., Savettieri G., et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 65 2 (Jul 2005) 280-285
18. Kalkers N., Ameziane N., Bot J., Minneboo A., Polman C., and Barkhof F. Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 59 10 (Oct 2002) 1572-1576
19. Giorgio A., Battaglini M., Smith S., and De Stefano N. Brain atrophy assessment in multiple sclerosis: importance and limitations. Neuroimaging Clin N Am 18 4 (Nov 2008) 675-686
20. Antulov R., Weinstock-Guttman B., Cox J., Hussein S., Durfee J., Caiola C., et al. Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Mult Scler 15 3 (Mar 2009) 345-354
21. Secondary Progressinv Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology 56 11 (Jun 2001) 1496-1504
22. Li D., Zhao G., and Paty D. and the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56 11 (Jun 2001) 1505-1513